[The application of the autologous serum eye drops results in significant improvement of the conjunctival status in patients with the dry eye syndrome].
OBJECTIVE
To detect the changes on the conjunctiva surface before and after the application of the autologous serum (AS) eye drops in patients with dry eye syndrome, using both clinical and laboratory approaches, supplemented with subjective assessing the discomfort status.


METHODS
The AS eye drops were applied during the period of 3 months in 8 patients with dry eye syndrome (Schirmer test < 5 mm and break-up time < 5 seconds), with the highest (maximum) frequency 8 times a day. The clinical (Schirmer test, break-up time, rose Bengal staining, examination of the tear meniscus, detritus and superficial punctate keratitis) and laboratory examinations (morphological assessment of the conjunctiva, detection of apoptotic cells) were performed at the start and at the end of the 3 months treatment period. Each day, patients reported their ocular status (dryness, discomfort, foreign body sensation, light sensitivity).


RESULTS
The AS eye drops application improved significantly the values of the Schirmer test, detritus and superficial punctate keratitis as well. The goblet cells density on the conjunctival surface increased and the number of apoptotic cells decreased. The intensity of unpleasant feelings reported by the patients decreased significantly in all of the assessed categories.


CONCLUSIONS
Because the application of AS eye drops caused the improvement of conjunctival status as well as the decrease of the severity of difficulties reported by the patients, the AS eye drops application should become common therapeutic practice in patients with dry eye syndrome.
Jirsová
K
K
Laborator biologie a patologie oka, Ustav dĕdicných metabolických poruch VFN a 1. LF UK, Praha. katerina.jirsova@vfn.cz
Hrdlicková
E
E
Alfakih
A
A
Juklová
K
K
Filipec
M
M
Faltus
V
V
Veselá
V
V
D000328:Adult; D000368:Aged; D003228:Conjunctiva / Q000473:pathology*; D015352:Dry Eye Syndromes / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D044967:Serum
D009883:Ophthalmic Solutions